Spectrum Pharmaceuticals Announces Completion Of NDA Filing For Satraplatin For Hormone Refractory Prostate Cancer

... Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) today announced the completion of the submission of the New Drug Application (NDA) to the US Food & Drug Administration (FDA) for satraplatin, the Company's lead drug candidate for the treatment of hormone refractory prostate cancer (HRPC) for those patients who have failed prior chemotherapy. [click link for full article] ...